

projected Heads-Up Display (HUD) to cue weapons and aircraft sensors to air and ground targets. This system projects visual targeting and aircraft performance information on the back of the helmet's visor, enabling the pilot to monitor this information without interrupting his field of view through the cockpit canopy. This provides significant improvement for close combat targeting and engagement. The JHMCS hardware is Unclassified; technical data and documentation are classified up to Secret.

14. If a technologically advanced adversary were to obtain knowledge of the specific hardware and software elements, the information could be used to develop countermeasures which might reduce weapon system effectiveness or be used in the development of a system with similar or advanced capabilities.

[FR Doc. 2011-32284 Filed 12-16-11; 8:45 am]

BILLING CODE 5001-06-P

## DEPARTMENT OF DEFENSE

### Office of the Secretary

#### Notice of Intent To Grant an Exclusive License; Voltage Networking, LLC; Correction

**AGENCY:** National Security Agency, Department of Defense (DoD).

**ACTION:** Notice; correction.

**SUMMARY:** On November 10, 2011 (76 FR 70117-70118), DoD published a notice titled Notice of Intent to Grant an Exclusive License; Voltage Networking, LLC. In the **SUMMARY** section, in the fourth line, the word "non-assignable" was incorrectly published. This notice corrects that error.

**FOR FURTHER INFORMATION CONTACT:** Marian T. Roche, Director, Technology Transfer Program, 9800 Savage Road, Suite 6541, Fort George G. Meade, MD 20755-6541, telephone (443) 479-9569.

**SUPPLEMENTARY INFORMATION:** On November 10, 2011, DoD published a notice titled Notice of Intent to Grant an Exclusive License; Voltage Networking, LLC. Subsequent to the publication of that notice, DoD discovered that the word "non-assignable" in the fourth line of the **SUMMARY** section had been inadvertently published.

#### Correction

In the notice (FR Doc. 2011-29064) published on November 10, 2011 (76 FR 70117-70118), make the following correction. On page 70117, in the third column, in the **SUMMARY** section, beginning in the first line, the text "The

National Security Agency hereby gives notice of its intent to grant Voltage Networking, LLC a revocable, non-assignable, exclusive, license to practice the following Government-Owned inventions as described in the following:" should read "The National Security Agency hereby gives notice of its intent to grant Voltage Networking, LLC a revocable exclusive license to practice the following Government-Owned inventions as described in the following:".

Dated: December 14, 2011.

**Aaron Siegel,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

[FR Doc. 2011-32405 Filed 12-16-11; 8:45 am]

BILLING CODE 5001-06-P

## DEPARTMENT OF DEFENSE

### Office of the Secretary

#### Meeting of the Uniform Formulary Beneficiary Advisory Panel

**AGENCY:** Assistant Secretary of Defense (Health Affairs), DoD.

**ACTION:** Notice of meeting.

**SUMMARY:** Under the provisions of the Federal Advisory Committee Act of 1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and the Government in the Sunshine Act of 1976 (Title 5, U.S.C., Section (Sec.) 552b, as amended) the Department of Defense (DoD) announces the following Federal Advisory Committee Meeting:

*Name of Committee:* Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel).

**DATES:** January 12, 2012, from 9 a.m.-1 p.m.

**ADDRESSES:** Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004.

**FOR FURTHER INFORMATION CONTACT:** CDR Joseph Lawrence, DFO, Uniform Formulary Beneficiary Advisory Panel, 4130 Stanley Road, Suite 208, Building 1000, San Antonio, TX 78234-6012; Telephone: (210) 295-1271 Fax: (210) 295-2789; Email Address: [Baprequests@tma.osd.mil](mailto:Baprequests@tma.osd.mil).

#### SUPPLEMENTARY INFORMATION:

*Purpose of Meeting:* The Panel will review and comment on recommendations made to the Director of TRICARE Management Activity, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.

#### Meeting Agenda

1. Sign-In.

2. Welcome and Opening Remarks.  
3. Public Citizen Comments.  
4. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item):  
a. Antidepressants and Non-Opioid Pain Syndrome Agents.  
b. Pulmonary-1 Agents: Short Acting Beta Agonists.  
c. Phosphodiesterase-5 Inhibitors for Erectile Dysfunction.  
d. Designated Newly Approved Drugs in Already-Reviewed Classes.  
e. Pertinent Utilization Management Issues.

5. Panel Discussions and Vote.  
*Meeting Accessibility:* Pursuant to Title 5, U.S.C., Sec. 552b, as amended, and Title 41, Code of Federal Regulations (CFR), Sec. 102-3.140 through 102-3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly.

*Administrative Work Meeting:* Prior to the public meeting, the Panel will conduct an Administrative Work Meeting from 7:30 a.m. to 9 a.m. to discuss administrative matters of the Panel. The Administrative Work Meeting will be held at the Naval Heritage Center, 701 Pennsylvania Avenue NW., Washington, DC 20004. Pursuant to Title 41, CFR, § 102-3.160, the Administrative Work Meeting will be closed to the public.

*Written Statements:* Pursuant to Title 41, CFR, §§ 102-3.105(j) and 102-3.140, the public or interested organizations may submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel's Designated Federal Officer (DFO). The DFO's contact information can be obtained from the General Services Administration's Federal Advisory Committee Act Database at <https://www.fido.gov/facadatabase/public.asp>.

Written statements that do not pertain to the scheduled meeting of the Panel may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting, then these statements must be submitted no later than 5 business days prior to the meeting in question. The DFO will review all submitted written statements and provide copies to all the committee members.

*Public Comments:* In addition to written statements, the Panel will set aside 1 hour for individuals or interested groups to address the Panel. To ensure consideration of their